MyChesCo on MSN2h
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab
Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...
Johnson & Johnson reports progress on nipocalimab
HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...
Killeen Daily Herald2d
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...
Could obesity drugs help with alcohol cravings? New study suggests potential
Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.
Endocrinology Advisor3d
January 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.